中國人壽(02628.HK)將於8月26日派發末期股息
格隆匯6月30日丨中國人壽(02628.HK)公佈,公司將派發截至2020年12月31日止年度末期股息每股人民幣0.64元(相等於每股0.76833港元)(含税)予於2021年7月14日(星期三)名列公司H股股東名冊的H股股東。根據公司章程規定,末期股息以人民幣計值及宣佈,而H股的末期股息則以港元支付。相關兑換率為按股東周年大會宣佈派發末期股息之日前一週中國人民銀行公佈的人民幣兑換港元平均收市價(人民幣0.83297元兑1.00港元)計算。
預期收款代理人將於2021年8月26日(星期四)派發末期股息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.